[go: up one dir, main page]

WO2024050039A3 - Methods and compositions for hydrodynamic gene delivery - Google Patents

Methods and compositions for hydrodynamic gene delivery Download PDF

Info

Publication number
WO2024050039A3
WO2024050039A3 PCT/US2023/031751 US2023031751W WO2024050039A3 WO 2024050039 A3 WO2024050039 A3 WO 2024050039A3 US 2023031751 W US2023031751 W US 2023031751W WO 2024050039 A3 WO2024050039 A3 WO 2024050039A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
hydrodynamic
delivery
gene delivery
hydrodynamic injection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2023/031751
Other languages
French (fr)
Other versions
WO2024050039A2 (en
Inventor
Robert Kruse
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hydrogene Therapeutics Inc
Original Assignee
Hydrogene Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hydrogene Therapeutics Inc filed Critical Hydrogene Therapeutics Inc
Priority to JP2025512908A priority Critical patent/JP2025529195A/en
Priority to CA3265882A priority patent/CA3265882A1/en
Priority to CN202380076280.1A priority patent/CN120166940A/en
Priority to EP23861314.5A priority patent/EP4580685A2/en
Priority to AU2023333051A priority patent/AU2023333051A1/en
Publication of WO2024050039A2 publication Critical patent/WO2024050039A2/en
Publication of WO2024050039A3 publication Critical patent/WO2024050039A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present disclosure relates to methods of pressure-guided hydrodynamic injection, into tissues such as kidney, pancreas, liver, common bile duct, etc., in certain embodiments for delivery of nucleic acids or viral vectors. This includes optimal pressures that mediate gene delivery and expression into the subject during such hydrodynamic injection. Methods of disentangling individual differences to achieve target pressure during the hydrodynamic procedure are described, while also avoiding tissue injury, ruptures, tears, decreasing the toxicity of hydrodynamic injection, and other considerations relevant to therapeutic delivery.
PCT/US2023/031751 2022-08-31 2023-08-31 Methods and compositions for hydrodynamic gene delivery Ceased WO2024050039A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2025512908A JP2025529195A (en) 2022-08-31 2023-08-31 Methods and compositions for hydrodynamic gene delivery
CA3265882A CA3265882A1 (en) 2022-08-31 2023-08-31 Methods and compositions for hydrodynamic gene delivery
CN202380076280.1A CN120166940A (en) 2022-08-31 2023-08-31 Methods and compositions for hydrodynamic gene delivery
EP23861314.5A EP4580685A2 (en) 2022-08-31 2023-08-31 Methods and compositions for hydrodynamic gene delivery
AU2023333051A AU2023333051A1 (en) 2022-08-31 2023-08-31 Methods and compositions for hydrodynamic gene delivery

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US202263374058P 2022-08-31 2022-08-31
US202263374070P 2022-08-31 2022-08-31
US202263374228P 2022-08-31 2022-08-31
US202263374231P 2022-08-31 2022-08-31
US202263374073P 2022-08-31 2022-08-31
US202263374216P 2022-08-31 2022-08-31
US202263374234P 2022-08-31 2022-08-31
US63/374,073 2022-08-31
US63/374,234 2022-08-31
US63/374,070 2022-08-31
US63/374,216 2022-08-31
US63/374,058 2022-08-31
US63/374,228 2022-08-31
US63/374,231 2022-08-31

Publications (2)

Publication Number Publication Date
WO2024050039A2 WO2024050039A2 (en) 2024-03-07
WO2024050039A3 true WO2024050039A3 (en) 2024-04-11

Family

ID=90098626

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/031751 Ceased WO2024050039A2 (en) 2022-08-31 2023-08-31 Methods and compositions for hydrodynamic gene delivery

Country Status (6)

Country Link
EP (1) EP4580685A2 (en)
JP (1) JP2025529195A (en)
CN (1) CN120166940A (en)
AU (1) AU2023333051A1 (en)
CA (1) CA3265882A1 (en)
WO (1) WO2024050039A2 (en)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080097384A1 (en) * 2004-03-25 2008-04-24 Andrew Pacey Gene Therapy
US20080306403A1 (en) * 2005-02-28 2008-12-11 Jan Malm Method and Device for Determining the Hydrodynamics of the Cerebrospinal Fluid System
US20150072328A1 (en) * 2012-11-06 2015-03-12 Acist Medical Systems, Inc. Simulated contrast injection medium
US20160213896A1 (en) * 2013-08-30 2016-07-28 Indiana University Research & Technology Corporation Hydrodynamic method and apparatus for delivering fluids to kidney tissues
US20170015994A1 (en) * 2014-02-24 2017-01-19 Massachusetts Institute Of Technology Methods for in vivo genome editing
US20170216408A1 (en) * 2015-10-30 2017-08-03 Spark Therapeutics, Inc. CpG REDUCED FACTOR VIII VARIANTS, COMPOSITIONS AND METHODS AND USES FOR TREATMENT OF HEMOSTASIS DISORDERS
US20200345867A1 (en) * 2019-04-30 2020-11-05 The Johns Hopkins University Organ directed gene delivery
WO2022204535A1 (en) * 2021-03-25 2022-09-29 The Johns Hopkins University Hydrodynamic gene delivery

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080097384A1 (en) * 2004-03-25 2008-04-24 Andrew Pacey Gene Therapy
US20080306403A1 (en) * 2005-02-28 2008-12-11 Jan Malm Method and Device for Determining the Hydrodynamics of the Cerebrospinal Fluid System
US20150072328A1 (en) * 2012-11-06 2015-03-12 Acist Medical Systems, Inc. Simulated contrast injection medium
US20160213896A1 (en) * 2013-08-30 2016-07-28 Indiana University Research & Technology Corporation Hydrodynamic method and apparatus for delivering fluids to kidney tissues
US20170015994A1 (en) * 2014-02-24 2017-01-19 Massachusetts Institute Of Technology Methods for in vivo genome editing
US20170216408A1 (en) * 2015-10-30 2017-08-03 Spark Therapeutics, Inc. CpG REDUCED FACTOR VIII VARIANTS, COMPOSITIONS AND METHODS AND USES FOR TREATMENT OF HEMOSTASIS DISORDERS
US20200345867A1 (en) * 2019-04-30 2020-11-05 The Johns Hopkins University Organ directed gene delivery
WO2022204535A1 (en) * 2021-03-25 2022-09-29 The Johns Hopkins University Hydrodynamic gene delivery

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YUTING HUANG, ROBERT L. KRUSE, HUI DING, MOHAMAD I. ITANI, JONATHAN MORRISON, ZACK Z. WANG, FLORIN M. SELARU, VIVEK KUMBHARI: "Parameters of biliary hydrodynamic injection during endoscopic retrograde cholangio-pancreatography in pigs for applications in gene delivery", PLOS ONE, PUBLIC LIBRARY OF SCIENCE, US, vol. 16, no. 4, 28 April 2021 (2021-04-28), US , pages e0249931, XP093159546, ISSN: 1932-6203, DOI: 10.1371/journal.pone.0249931 *

Also Published As

Publication number Publication date
AU2023333051A1 (en) 2025-03-20
CN120166940A (en) 2025-06-17
WO2024050039A2 (en) 2024-03-07
EP4580685A2 (en) 2025-07-09
CA3265882A1 (en) 2024-03-07
JP2025529195A (en) 2025-09-04

Similar Documents

Publication Publication Date Title
MX2022010980A (en) Compositions and methods for targeted rna delivery.
WO2019094791A3 (en) Targeted crispr delivery platforms
WO2006060641A3 (en) Methods for targeted delivery of genetic material to the liver
Rajapaksha et al. Liver‐targeted angiotensin converting enzyme 2 therapy inhibits chronic biliary fibrosis in multiple drug‐resistant gene 2‐knockout mice
CN111511405A (en) Peptides and nanoparticles for intracellular delivery of mRNA
WO2023015223A3 (en) Compositions and methods for targeted rna delivery
MX2009001207A (en) Polyconjugates for in vivo delivery of polynucleotides.
JP7625033B2 (en) Double-stranded oligonucleotide structure containing androgen receptor specific sequence, and composition for preventing hair loss and promoting hair growth containing the same
KR20140051357A (en) Poly(vinyl ester) polymers for in vivo nucleic acid delivery
HUP9802665A2 (en) Composition for controlled release of miotic and mydriatic drugs in the anterior chamber
WO2022169913A3 (en) Synthetic degrader system for targeted protein degradation
WO2022256500A3 (en) Dll3 targeting trispecific proteins and methods of use
SG189942A1 (en) In vivo polynucleotide delivery conjugates having enzyme sensitive linkages
KR20160035081A (en) POLYCONJUGATES FOR DELIVERY OF RNAi TRIGGERS TO TUMOR CELLS IN VIVO
WO2007064846A3 (en) COMPOSITIONS AND METHODS OF USING siRNA TO KNOCKDOWN GENE EXPRESSION AND TO IMPROVE SOLID ORGAN AND CELL TRANSPLANTATION
AU2004269200A8 (en) Enhancing accumulation of heterologous polypeptides in plant seeds through targeted suppression of endogenous storage proteins
WO2023018990A3 (en) Lipids for nucleic acid delivery
WO2024050039A3 (en) Methods and compositions for hydrodynamic gene delivery
WO2008098569A3 (en) Biologically active molecules, particularly based on pna and sirna, method for the cell-specific activation thereof, and application kit to be administered
US5667777A (en) Delivery of gene products via mesangial cells
WO2024035783A3 (en) Sulfur-containing compounds and compositions thereof for delivery of nucleic acids
WO2023213983A3 (en) Expression construct
WO2023245061A8 (en) Lipid conjugates for the delivery of therapeutic agents to cns tissue
EP4360655A3 (en) Molecular guide system peptides and uses thereof
Zhang et al. Targeting hemostasis-related moieties for tumor treatment

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23861314

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2025512908

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: AU2023333051

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2023333051

Country of ref document: AU

Date of ref document: 20230831

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 202517030217

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2023861314

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2023861314

Country of ref document: EP

Effective date: 20250331

WWE Wipo information: entry into national phase

Ref document number: CN2023800762801

Country of ref document: CN

Ref document number: 202380076280.1

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23861314

Country of ref document: EP

Kind code of ref document: A2

WWP Wipo information: published in national office

Ref document number: 202380076280.1

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2023861314

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 202517030217

Country of ref document: IN